Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference

Journal of Diabetes Science and Technology
Mervi AndelinMarcus Lind

Abstract

Using the standard venous reference for the evaluation of continuous glucose monitoring (CGM) systems could possibly negatively affect measured CGM accuracy since CGM are generally calibrated with capillary glucose and venous and capillary glucose concentrations differ. We therefore aimed to quantify the effect of using capillary versus venous glucose reference samples on estimated accuracy in capillary calibrated CGM. We evaluated 41 individuals with type 1 diabetes mellitus (T1DM) using the Dexcom G4 CGM system over 6 days. Patients calibrated their CGM devices with capillary glucose by means of the HemoCue system. During 2 visits, capillary and venous samples were simultaneously measured by HemoCue and compared to concomitantly obtained CGM readings. The mean absolute relative difference (MARD) was calculated using capillary and venous reference samples. Venous glucose values were 0.83 mmol/L (15.0 mg/dl) lower than capillary values over all glycemic ranges, P < .0001. Below 4 mmol/l (72 mg/dl), the difference was 1.25 mmol/l (22.5 mg/dl), P = .0001, at 4-10 mmol/l (72-180 mg/dl), 0.67 mmol/l (12.0 mg/dl), P < .0001 and above 10 mmol/l (180 mg/dl), 0.95 mmol/l (17.1 mg/dl), P < .0001. MARD was 11.7% using capillary values as...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
May 23, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·K KuwaM Tominaga
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Sep 7, 2006·Statistics in Medicine·Stephen Senn
Mar 15, 2008·Diabetes Care·Boris KovatchevWilliam Clarke
Dec 8, 2011·Diabetes Technology & Therapeutics·Desmond Barry KeenanRajiv V Shah
Oct 16, 2012·Journal of Diabetes Science and Technology·Yoeri M LuijfUNKNOWN AP@home consortium
Dec 22, 2012·Diabetes Technology & Therapeutics·Lalantha LeelarathnaRoman Hovorka
May 9, 2013·Diabetes Technology & Therapeutics·Yoeri M LuijfUNKNOWN AP@home consortium
May 31, 2014·Journal of Diabetes Science and Technology·Edward R DamianoSteven J Russell
Nov 20, 2014·The New England Journal of Medicine·Marcus LindAnnika Rosengren
Dec 2, 2014·Diabetes Technology & Therapeutics·Boris P KovatchevMarc D Breton
Jan 7, 2015·JAMA : the Journal of the American Medical Association·Shona J LivingstoneUNKNOWN Scottish Renal Registry
Apr 9, 2015·Journal of Diabetes Science and Technology·Stefan PleusGuido Freckmann
May 16, 2015·Diabetes Technology & Therapeutics·Boris P Kovatchev

❮ Previous
Next ❯

Citations

Oct 13, 2016·Indian Journal of Endocrinology and Metabolism·Anjana HulseK M Prasanna Kumar
Jun 7, 2017·Diabetes Technology & Therapeutics·Jessica R CastleBoris Kovatchev
Jan 14, 2020·Diabetes Technology & Therapeutics·Yotam AmarEran Segal
Jun 21, 2019·Journal of Diabetes Science and Technology·Lutz HeinemannLuigi Del Re
Oct 27, 2020·Journal of Diabetes Science and Technology·Sheyda SofizadehMarcus Lind
Mar 10, 2021·Journal of Diabetes Science and Technology·Jessica Hanae Zafra-TanakaAntonio Bernabe-Ortiz
Jun 1, 2021·Journal of Theoretical Biology·Andrea De GaetanoElvin J Moore

❮ Previous
Next ❯

Software Mentioned

HemoCue
MARD
SAS

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.